AcceleRating the Translation of virtual twins towards a pErsonalised Management of fatty lIver patients (Artemis)

加速虚拟双胞胎向脂肪肝患者个性化管理的转化（Artemis）

• 批准号: 10109933
• 金额: $ 36.82万
• 依托单位: IMPERIAL COLLEGE LONDON
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10109933
• 关键词: AcceleRating; Translation; virtual; twins; towards

The ARTEMIs project aims to consolidate existing computational mechanistic and machine-learning models at different scales to deliver ‘virtual twins’ embedded in a clinical decision support system (CDSS). The CDSS will provide clinically meaningful information to clinicians, for a more personalised management of the whole spectrum of Metabolic Associated Fatty Liver Disease (MAFLD). MAFLD, with an estimated prevalence of about 25%, goes from an undetected sleeping disease, to inflammation (hepatitis), to fibrosis development (cirrhosis) and/or hepatocellular carcinoma (HCC), decompensated cirrhosis and HCC being the final stages of the disease. However, many MAFLD patients do not die from the liver disease itself, but from cardiovascular comorbidities or complications. The ARTEMIs will contribute to the earlier management of MAFLD patients, by prognosing the development of more advanced forms of the disease and cardiovascular comorbidities, promoting active surveillance of patients at risk. The system will predict the impact of novel drug treatments or procedures, or simply better life habits. The system will therefore not only serve as a clinical decision aid tool, but also as an educational tool for patients, to promote better nutritional and lifestyle behaviors. In more advanced forms of the disease, therapeutic interventions include TIPPS to manage portal hypertension, partial hepatectomy, partial or complete liver transplant. ARTEMIs will contribute to predict per- or post-intervention heart failure, building on existing microcirculation hemodynamics models. The model developers will benefit from a large distributed patient cohort and data exploration environment to identify patterns in data, draw new theories on the liver-heart metabolic axis and validate the performance of their models. The project includes a proof-of-concept feasibility study assessing the utility of the integrated virtual twins and CDSS in the clinical context.

Artemis项目旨在在不同尺度上巩固现有的计算机械和机器学习模型，以提供嵌入临床决策支持系统（CDSS）中的“虚拟双胞胎”。 CDSS将为临床医生提供临床上有意义的信息，以更加个性化的管理代谢相关的脂肪肝病（MAFLD）。 MAFLD估计患病率约为25％，从未发现的睡眠疾病，炎症（肝炎），纤维化发育（肝硬化）和/或肝细胞癌（HCC）（HCC），分解的Cirrhosis和HCC是该疾病的最终阶段。但是，许多黑手党患者并非因肝病本身而死亡，而是因心血管合并症或并发症而死亡。 Artemis将通过预测疾病和心血管合并症的更高级形式的发展来为MAFLD患者的早期治疗做出贡献，从而促进对处于危险的患者的积极监视。该系统将预测新型药物治疗或程序的影响，或者只是更好的生活习惯。因此，该系统不仅将用作临床决策援助工具，而且还将作为患者的教育工具，以促进更好的营养和生活方式行为。在疾病的更高级形式中，热干预措施包括用于管理门户高血压，部分肝术，部分或完整肝移植的TIPP。 Artemis将在现有的微循环血液动力学模型的基础上预测干预后心力衰竭或后心力衰竭。模型开发人员将受益于大型分布式患者队列和数据探索环境，以识别数据中的模式，绘制有关活心身代谢轴的新理论，并验证其模型的性能。该项目包括一项概念验证可行性研究，该研究评估了临床背景下综合虚拟双胞胎和CDS的实用性。